Company: AEMD
Filing Date: 2025-02-12
Form Type: 10-Q
Source: 0001683168-25-000960
Chunk: 86

Company: AETHLON MEDICAL INC
Filing Date: 2025-02-12
Form: 10-Q
Item: Item 2
Chunk 86
---
 5,650,000
shares of common stock, at a combined public offering price of $0.579 per pre-funded warrant and accompanying warrants, which is equal
to the public offering price per share of common stock and accompanying warrants, less the $0.001 per share exercise price of each such
pre-funded warrant.

All pre-funded warrants issued in the offering
were exercised in the quarter ended June 30, 2024. The Class A and Class B warrants each have an
exercise price of $0.58 per share, are immediately exercisable, and, in the case of Class A warrants, will expire on May 17, 2029, and
in the case of Class B warrants, will expire on May 19, 2025. The exercise price of the Class A and Class B warrants is also subject to
adjustment for stock splits, reverse splits, and similar capital transactions as described in such warrants.

Maxim Group LLC (“Maxim”),
served as the exclusive placement agent in connection with the offering. We paid Maxim a cash fee of 6.5% of the aggregate gross proceeds
raised at the closing of the offering, and reimbursement of certain expenses and legal fees in the amount of $100,000. We also issued
to designees of Maxim warrants to purchase up to an aggregate of 324,000 shares of common stock (the “Placement Agent Warrants”).
The Placement Agent Warrants have an exercise price of $0.58 per share and have substantially the same terms as the Class A warrants,
except the Placement Agent Warrants are not subject to an exercise price reset, are non-exercisable until November 15, 2024, and will
expire on May 15, 2029.

The gross proceeds from
the offering, before deducting the placement agent’s fees and other offering expenses, were approximately $4.7 million. Net proceeds,
of the offering, after deducting the placement agent fees and expenses and other offering expenses payable by us, were approximately $3.5
million.

The shares of common
stock, the Class A and Class B warrants, the pre-funded warrants and the Placement Agent Warrants described above and the underlying shares
of common stock were offered pursuant to a Registration Statement on Form S-1, as amended (File No. 333-278188), which was declared effective
by the SEC on May 15, 2024.

Warrant Exercises

In June 2024, and